Podcast
BioCentury This Week
Hosted by BioCentury · EN
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
38episodes
Episodes
Newest firstAll episodes
Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
1w ago00:31:43Tap to summarizePressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how stakeholders in the U.S. are responding to the challenge.The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last week.View full story: https://www.biocentury.com/article/660433#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning00:00- Introduction01:15 - Academic Centers10:42 - Policy Picture15:48 - Grand Rounds Europe Highlights18:01 - Federated Learning28:15 - NASDAQ IPOsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
2w ago00:32:25Tap to summarizeRumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it.The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression.View full story: https://www.biocentury.com/article/660376#BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus00:00 - Introduction00:51 - AZ-BMS Rumors08:07 - Replimune20:46 - PsychedelicsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
3w ago00:34:09Tap to summarizeArgenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal and put it in the context of a new cohort of large-cap companies increasingly active in biotech M&A.The analysts also assess how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one another. Finally, they analyze the 1H26 clinical and regulatory catalyst scorecard, which therapies hit their milestones, which missed, and what’s next through year-end. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660296#BiotechMA #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #Biopharma00:01 - Sponsor Message: CBRE01:57 - BioCentury AI Connector05:47 - Argenx Acquires Forte08:06 - Rise of Biotech Buyers13:12 - AI Giants' Tech Stack24:20 - Anthropic Enters Drug Development27:41 - 2026 CatalystTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
4w ago00:42:07Tap to summarizeThe departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallance’s exit, the appointment of John Healey as Chancellor of the Exchequer and other changes arriving with the new Prime Minister could mean for life sciences in the country. BioCentury’s analysts also discuss an ambitious U.K. data initiative launched this month. The Health Data Research Service is intended to be a single front door to all NHS health records, offering large-scale longitudinal health data across diverse populations.Beyond the U.K., the team turns to companies to watch in Taiwan, what’s next for Biogen’s anti-tau therapy, Eli Lilly’s proposed acquisition of psychedelics company AtaiBeckley, and the latest changes at FDA. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660194#Biotech #LifeSciences #UKBiotech #HealthData #FDA00:01 - Sponsor Message: CBRE02:23 - U.K. Leadership Changes09:21 - U.K. Data Initiative10:52 - Taiwan Biotech16:44 - Biogen’s Tau Data27:18 - Lilly’s Psychedelics Takeout28:20 - FDATo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Jul 1500:29:16Tap to summarizeAfter nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury’s analysts to discuss the company’s recent report on life sciences talent trends, and how those trends are driving property demand. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#LifeSciences #BiotechJobs #Workforce #LifeSciencesRealEstate #Talent00:01 - Sponsor Message: CBRE00:45 - Industry Inflection Point04:17 - Report Methodology10:08 - Growth Beyond Big Hubs15:28 - Capital Markets Signals18:48 - AI and Space Use20:50 - Emerging Talent26:34 - Up-and-Coming CitiesTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 376 - M&A momentum: 3Q public markets preview
Jul 1400:33:01Tap to summarizeM&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust?Editor in Chief Simone Fishburn gives her perspective on what incoming Prime Minister Andy Burnham’s agenda means for U.K. life sciences. The analysts also discuss Ionis’ ATTR-CM miss and Takeda’s orexin program. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#BiotechMA #BiotechInvesting #PublicMarkets #LifeSciences #DrugDevelopment00:01 - Sponsor Message: CBRE01:46 - 3Q Market Preview10:54 - Burnham’s Britain19:40 - Ionis' ATTR-CM Miss29:12 - Takeda Orexin ProgramTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Jul 700:33:44Tap to summarizeNovartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit.The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson’s atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress’ probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660033#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech00:01 - Sponsor Message: CBRE01:15 - Novartis Buying Myricx08:01 - U.K. Regulation14:44 - DeGette & FDA Reform21:51 - Parkinson's Atlas Insights29:39 - China Trials ProbeTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 374 - Parkinson's deep dive & FDA trial reforms
Jun 2900:34:14Tap to summarizeNew Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape.The team then turns to AstraZeneca’s build-out of its obesity portfolio, followed by FDA’s Operation TrialBlazer and what the reforms mean for reducing the time to launch a clinical trial in the U.S. — and whether they can help close the gap with China.Finally, the analysts review recent FDA reversals of controversial regulatory decisions made under former Commissioner Marty Makary’s leadership and whether companies and investors can expect this reversion to the mean to carry forward.View full story: https://www.biocentury.com/article/659958#ParkinsonsDisease #ObesityDrugDevelopment #FDA #ClinicalTrials #DrugDevelopment00:00 - Introduction01:40 - Parkinson's New Targets11:43 - AstraZeneca's Obesity Pipeline18:37 - FDA's Operation TrialBlazer27:33 - FDA Leadership OutlookTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Jun 2300:30:10Tap to summarizeAbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeout and the assets AbbVie gains.The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency’s former leadership and assess Acting CDER Director Michael Davis’ memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA.Finally, they discuss China NMPA’s first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen.View full story: https://www.biocentury.com/article/659864#BiotechMA #Immunology #FDA #CART #ChinaBiotech00:59 - AbbVie Buys Apogee05:20 - uniQure U-turn09:02 - FDA Reversals12:32 - Tzield Memo20:53 - Solid Tumor CAR T ApprovalTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Jun 1600:25:13Tap to summarizeBiotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut by Parabilis, the largest IPO in the sector’s history.The analysts also discuss the Biosecure Act and U.S. policy toward China; the cachexia pipeline; and BioCentury’s updated Innovation Distillery.View full story: https://www.biocentury.com/article/659773 #BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech 00:36 - Innovation Distillery03:56 - Biotech IPOs10:13 - Biosecure Act, WuXi AppTec16:03 - Cachexia Pipeline22:03 - Ouster for RFK Jr.?To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Transcribe →